Galectin Therapeutics (GALT) vs Vicore Pharma AB (VCRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Galectin Therapeutics is the larger company by market cap ($271.4 million vs $264.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GALT | VCRE |
|---|---|---|
| Share price | $2.69 | $9.41 |
| Market cap | $271.35M | $264.89M |
| 1-day change | -4.27% | -5.09% |
| YTD return | -35.34% | — |
| 1-year return | -49.72% | — |
| 5-year return | +4.67% | — |
| EPS (TTM) | $-0.32 | $-2.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-30.84M | — |
| 52-week high | $7.13 | $17.80 |
| 52-week low | $2.03 | $7.88 |
| Distance from 52-week high | -62.27% | -47.16% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +308.92% | +158.90% |
| Average volume | 252.31K | 23.31K |
| Shares outstanding | 100.88M | 28.16M |
| Employees | 9 | 50 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Galectin Therapeutics
GALT stock →Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
About Vicore Pharma AB
VCRE stock →Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 50 employees
GALT vs VCRE FAQ
Which is bigger, Galectin Therapeutics or Vicore Pharma AB?
Galectin Therapeutics (GALT) is larger, with a market capitalization of $271.35M compared with $264.89M for Vicore Pharma AB (VCRE).
Are Galectin Therapeutics and Vicore Pharma AB in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.